Publications from the AffiliateMarketIngtools of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes We Treat You (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.
Released: March 15, 2012
Advances in medical treatment have made it possible for people infected with HIV to live longer, healthier lives. The CDC estimates that 1.2 million people live with HIV in the United States, with approximately 50,000 people newly infected each year. People with HIV require continuous access to quality care and treatment for HIV as well as their other health conditions. The White House Office of National AIDS Policy asked the IOM to identify core indicators related to continuous HIV care and access to supportive services, and to monitor the effect of both the National HIV/AIDS Strategy and Patient Protection and Affordable Care Act on improving HIV care.
Released: February 29, 2012
The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation’s children.
Released: February 23, 2012
Nearly 69 percent of U.S. adults and 32 percent of children are either overweight or obese, creating an annual medical cost burden that may reach $147 billion. Researchers and policy makers are eager to identify improved measures of environmental and policy factors that contribute to obesity prevention. The IOM formed the Committee on Accelerating Progress in Obesity Prevention to review the IOM’s past obesity-related recommendations, identify a set of recommendations for future action, and recommend indicators of progress in implementing these actions. The committee held a workshop in March 2011 about how to improve measurement of progress in obesity prevention.
Released: February 16, 2012
Scientific advances over the last decade now indicate that Alzheimer’s disease is a continuous, progressive cognitive disease, most likely beginning many years before dementia is apparent. To discuss the next steps in validating new diagnostic guidelines for Alzheimer’s disease, the IOM Forum on Neuroscience and Nervous System Disorders hosted a public workshop session at the Alzheimer’s Association International Conference.
Released: February 14, 2012
Deductible, co-insurance, out-of-pocket limits. Even to those with a basic understanding of health insurance, terms like these can be difficult to explain and understand. Under the Affordable Care Act of 2010, many more Americans will be eligible for health insurance through state insurance exchanges by 2014. Many of these individuals are among the 90 million American adults who lack basic health literacy. The IOM held a workshop that focused on ways in which health literate communication techniques can improve communication to potential enrollees.
Released: January 31, 2012
The epidemic of chronic illness is steadily moving towards crisis proportions, yet maintaining or enhancing quality of life for individuals living with these illnesses has not been given the attention it deserves. In this report, the IOM makes recommendations to the CDC as well as HHS on the development and support of programs to meet the health and social needs of people living with chronic illnesses.
Released: January 23, 2012
When a nation or region prepares for public health emergencies such as a pandemic influenza, a large-scale earthquake, or any major disaster scenario in which the health system may be destroyed or stressed to its limits, it is important to describe how standards of care would change due to shortages of critical resources. At the 17th World Congress on Disaster and Emergency Medicine, the IOM Forum on Medical and Public Health Preparedness sponsored a session that focused on the promise of and challenges to integrating crisis standards of care principles into international disaster response plans.
Released: January 13, 2012
In 2010, the IOM released a report that found, among other things, data not being reported by sex had slowed progress in women’s health. The number of women participating in clinical trials has increased over the last two decades, though they are still underrepresented. Even when women are included in these trials, however, the results are often not analyzed separately by sex. On August 30, 2011, The IOM’s Board on Population Health and Public Health Practice hosted a workshop to address the recommendation that journals should adopt a guideline that all papers report the outcomes of research on males and females separately.
Released: December 21, 2011
The development and application of regulatory science – which FDA has defined as the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products – calls for a well-trained, scientifically engaged, and motivated workforce. FDA faces challenges in retaining regulatory scientists and providing them with opportunities for professional development. In the private sector, advancement of innovative regulatory science in drug development has not always been clearly defined, well coordinated, or connected to the needs of the agency. As a follow-up to a 2010 workshop, the IOM held a workshop on September 20-21, 2011, to provide a format for establishing a specific agenda to implement the vision and principles relating to a regulatory science workforce and disciplinary infrastructure as discussed in the 2010 workshop.
Released: December 15, 2011
For many years, experiments using chimpanzees have been instrumental in advancing scientific knowledge and have led to new medicines to prevent life-threatening and debilitating diseases. However, recent advances in alternate research tools have rendered chimpanzees largely unnecessary as research subjects. The IOM, in collaboration with the National Research Council, conducted an in-depth analysis of the scientific necessity of chimpanzees for NIH-funded biomedical and behavioral research. The committee concludes that while the chimpanzee has been a valuable animal model in the past, most current biomedical research use of chimpanzees is not necessary, though noted that that it is impossible to predict whether research on emerging or new diseases may necessitate chimpanzees in the future.